Publicacions - IR Sant Pau

Cercar

01/07/2022 Beyond plaque psoriasis - pathogenesis and treatment of other psoriasis phenotypes

Iznardo, H, Puig, L. Beyond plaque psoriasis - pathogenesis and treatment of other psoriasis phenotypes. CURRENT OPINION IN RHEUMATOLOGY. 2022; 34(4)DOI:10.1097/BOR.0000000000000882. PMID:35699337. IF:5.100(Q2/3D).

01/07/2022 Nemolizumab: An Innovative Biologic Treatment to Control Interleukin 31, a Key Mediator in Atopic Dermatitis and Prurigo Nodularis

Serra-Baldrich, E, Santamaria-Babi, LF, Silvestre, JF. Nemolizumab: An Innovative Biologic Treatment to Control Interleukin 31, a Key Mediator in Atopic Dermatitis and Prurigo Nodularis. Actas Dermo-Sifiliograficas. 2022; 113(7)DOI:10.1016/j.ad.2021.12.014. PMID:35842249. IF:(Q/D).

01/06/2022 Ixekizumab Citrate-Free Formulation: Results from Two Clinical Trials

Chabra, S, Gill, BJ, Gallo, G, Zhu, DT, Pitou, C, Payne, CD, Accioly, A, Puig, L. Ixekizumab Citrate-Free Formulation: Results from Two Clinical Trials. ADVANCES IN THERAPY. 2022; 39(6)DOI:10.1007/s12325-022-02126-0. PMID:35449322. IF:3.800(Q2/4D).

01/06/2022 A cohort study of guselkumab in the treatment of psoriasis refractory to previous biologic therapies: effectiveness, safety and adherence

Medina-Catalan, D, Riera, P, Pages-Puigdemont, N, Masip, M, Lopez-Ferrer, A, Vilarrasa, E, Puig, L. A cohort study of guselkumab in the treatment of psoriasis refractory to previous biologic therapies: effectiveness, safety and adherence. International Journal of Clinical Pharmacy. 2022; 44(3)DOI:10.1007/s11096-022-01400-z. PMID:35380392. IF:2.400(Q3/8D).

01/06/2022 Indirect Treatment Comparison of Baricitinib versus Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis

de Bruin-Weller, MS, Serra-Baldrich, E, Barbarot, S, Grond, S, Schuster, C, Petto, H, Capron, JP, Raibouaa, A, Werfel, T. Indirect Treatment Comparison of Baricitinib versus Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis. Dermatology and Therapy. 2022; 12(6)DOI:10.1007/s13555-022-00734-w. PMID:35543919. IF:3.400(Q2/3D).

01/05/2022 Efficacy of early transfusion of convalescent plasma with high-titer SARS-CoV-2 neutralizing antibodies in hospitalized patients with COVID-19

Sanz, C, Nomdedeu, M, Pereira, A, Sauleda, S, Alonso, R, Bes, M, Brillembourg, H, Garcia-Vidal, C, Millan, A, Martinez-Llonch, N, Piron, M, Puerta-Alcalde, P, Puig, L, Rico, V, Soriano, A. Efficacy of early transfusion of convalescent plasma with high-titer SARS-CoV-2 neutralizing antibodies in hospitalized patients with COVID-19. TRANSFUSION. 2022; 62(5)DOI:10.1111/trf.16863. PMID:35338710. IF:2.900(Q3/7D).

01/05/2022 The biological basis of disease recurrence in psoriasis: a historical perspective and current models

Puig, L, Costanzo, A, Munoz-Elias, EJ, Jazra, M, Wegner, S, Paul, CF, Conrad, C. The biological basis of disease recurrence in psoriasis: a historical perspective and current models. BRITISH JOURNAL OF DERMATOLOGY. 2022; 186(5)DOI:10.1111/bjd.20963. PMID:34939663. IF:10.300(Q1/1D).

01/05/2022 Unmet Needs in the Management of Moderate-to-Severe Psoriasis in Spain: A Multidimensional Evaluation

Zozaya, N, Villoro, R, Abdalla, F, Alfonso Zamora, S, Balea Filgueiras, J, Carrascosa Carrillo, JM, Delgado Sanchez, O, Dolz Sinisterra, F, Garcia-Ruiz, A, Herranz Pinto, P, Manfredi, A, Martinez Olmos, J, Morales De los Rios Luna, P, Puig Sanz, L, Ros, S, Hildago-Vega, A. Unmet Needs in the Management of Moderate-to-Severe Psoriasis in Spain: A Multidimensional Evaluation. ACTA DERMATO-VENEREOLOGICA. 2022; 102DOI:10.2340/actadv.v102.583. PMID:35312022. IF:3.600(Q1/3D).

01/05/2022 Nail Psoriasis

Canal-Garcia, E, Bosch-Amate, X, Belinchon, I, Puig, L. Nail Psoriasis. Actas Dermo-Sifiliograficas. 2022; 113(5)DOI:10.1016/j.ad.2022.01.006. PMID:35697407. IF:(Q/D).

01/05/2022 Risk of a Second Skin Cancer in a Cohort of Patients With Nonmelanoma Skin Cancer - Basal Cell Carcinoma or Squamous Cell Carcinoma - Treated With Mohs Micrographic Surgery: A National Prospective Cohort Study

Medrano, RM, Estebaranz, JLL, Sanmartin-Jimenez, O, Garces, JR, Rodriguez-Prieto, MA, Vilarrasa-Rull, E, De Eusebio-Murillo, E, Escutia-Munoz, B, Florez-Menendez, A, Artola-Igarza, JL, Alfaro-Rubio, A, Redondo, P, Delgado-Jimenez, Y, Sanchez-Schmidt, JM, Allende-Markixana, I, Alonso-Pacheco, ML, Garcia-Bracamonte, B, De la Cueva-Dobao, P, Navarro-Tejedor, R, Ciudad-Blanco, C, Carnero-Gonzalez, L, Vazquez-Veiga, H, Cano-Martinez, N, Ruiz-Salas, V, Sanchez-Sambucety, P, Botella-Estrada, R, Gonzalez-Sixto, B, Martorell-Calatayud, A, Gil, P, Morales-Gordillo, V, Toll-Abello, A, Ocerin-Guerra, I, Mayor-Arenal, M, Suarez-Fernandez, R, Sainz-Gaspar, L, Descalzo, MA, Garcia-Doval, I. Risk of a Second Skin Cancer in a Cohort of Patients With Nonmelanoma Skin Cancer - Basal Cell Carcinoma or Squamous Cell Carcinoma - Treated With Mohs Micrographic Surgery: A National Prospective Cohort Study. Actas Dermo-Sifiliograficas. 2022; 113(5)DOI:10.1016/j.ad.2022.01.035. PMID:. IF:(Q/D).

01/04/2022 Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis

Blauvelt, A, Tsai, TF, Langley, RG, Miller, M, Shen, YK, You, Y, Yang, YW, Papp, KA, Puig, L. Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2022; 86(4)DOI:10.1016/j.jaad.2021.11.004. PMID:34798201. IF:13.800(Q1/1D).

01/03/2022 From Messengers to Receptors in Psoriasis: The Role of IL-17RA in Disease and Treatment (vol 22, 6740, 2021)

Vidal, S, Puig, L, Carrascosa-Carrillo, JM, Gonzalez-Cantero, A, Ruiz-Carrascosa, JC, Velasco-Pastor, AM. From Messengers to Receptors in Psoriasis: The Role of IL-17RA in Disease and Treatment (vol 22, 6740, 2021). INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2022; 23(5)DOI:10.3390/ijms23052649. PMID:35270045. IF:5.600(Q1/3D).

01/01/2022 Effect of Hepatitis E Virus RNA Universal Blood Donor Screening, Catalonia, Spain, 2017-2020

Bes, M, Costafreda, MI, Riveiro-Barciela, M, Piron, M, Rico, A, Quer, J, Puig, L, Sauleda, S. Effect of Hepatitis E Virus RNA Universal Blood Donor Screening, Catalonia, Spain, 2017-2020. EMERGING INFECTIOUS DISEASES. 2022; 28(1)DOI:10.3201/eid2801.211466. PMID:34932460. IF:11.800(Q1/1D).

01/01/2022 A Specialized Therapeutic Approach to Chronic Urticaria Refractory to H1-Antihistamines Improves Disease Burden: The Spanish AWARE Experience

Gimenez-Arnau, A, Bartra, J, Ferrer, M, Jauregui, I, Borbujo, J, Figueras, I, Munoz-Bellido, F, Pedraz, J, Serra-Baldrich, E, Tejedor-Alonso, M, Velasco, M, Terradas, P, Labrador, M. A Specialized Therapeutic Approach to Chronic Urticaria Refractory to H1-Antihistamines Improves Disease Burden: The Spanish AWARE Experience. JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY. 2022; 32(3)DOI:10.18176/jiaci.0661. PMID:33349612. IF:7.200(Q1/2D).

31/12/2023 Immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in patients receiving secukinumab: a literature review

Gisondi P., Simon D., Alarcon I., Pournara E., Puig L.. Immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in patients receiving secukinumab: a literature review. JOURNAL OF DERMATOLOGICAL TREATMENT. 2023; 34(1)DOI:10.1080/09546634.2023.2167487. PMID:36625506. IF:2.900(Q2/4D).

01/07/2023 Reddish and edematous nodules in an immunosuppressed patient

Mateu-Arrom, L, Rusinol, L, Puig, L. Reddish and edematous nodules in an immunosuppressed patient. INTERNATIONAL JOURNAL OF DERMATOLOGY. 2023; 62(7)DOI:10.1111/ijd.16512. PMID:36371702. IF:3.500(Q1/3D).

01/05/2023 Bullous eruption in a pluripathological patient

Rusinol, L, Carmona-Rocha, E, Spertino, J. Bullous eruption in a pluripathological patient. INTERNATIONAL JOURNAL OF DERMATOLOGY. 2023; 62(5)DOI:10.1111/ijd.16590. PMID:36683133. IF:3.500(Q1/3D).

01/05/2023 Perception of the need for dietary advice and dietary modifications in inflammatory bowel disease patients

Gely C., Gordillo J., Bertoletti F., González-Muñoza C., López A., García-Planella E.. Perception of the need for dietary advice and dietary modifications in inflammatory bowel disease patients. Gastroenterologia y Hepatologia. 2023; 46(5)DOI:10.1016/j.gastrohep.2022.10.005. PMID:36243252. IF:2.200(Q3/6D).

01/04/2023 Generalized pustular psoriasis: A global Delphi consensus on clinical course, diagnosis, treatment goals and disease management

Puig L., Choon S.E., Gottlieb A.B., Marrakchi S., Prinz J.C., Romiti R., Tada Y., von Bredow D., Gooderham M.. Generalized pustular psoriasis: A global Delphi consensus on clinical course, diagnosis, treatment goals and disease management. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2023; 37(4)DOI:10.1111/jdv.18851. PMID:36606566. IF:8.500(Q1/1D).

31/03/2023 Patch Testing in Patients With Severe Atopic Dermatitis Treated With Dupilumab: A Multicentric Approach in Spain

Docampo-Simon, A, Sanchez-Pujol, MJ, Pastor-Nieto, MA, Gimenez-Arnau, A, Rodriguez-Serna, M, Serra-Baldrich, E, Miquel, J, Sanchez-Perez, J, Sanz-Sanchez, T, Zaragoza-Ninet, V, Sanchez-Pedreno, P, Carrascosa, JM, Gatica-Ortega, ME, Fernandez-Redondo, V, Cordoba-Guijarro, S, Gonzalez-Perez, R, Silvestre, JF. Patch Testing in Patients With Severe Atopic Dermatitis Treated With Dupilumab: A Multicentric Approach in Spain. Dermatitis. 2023; 34(4)DOI:10.1089/derm.2022.0023. PMID:37001174. IF:4.000(Q1/2D).

13/03/2023 Allergen sensitization stratifies IL-31 production by memory T cells in atopic dermatitis patients

Sans-de San Nicolàs L., Figueras-Nart I., García-Jiménez I., Bonfill-Ortí M., Guilabert A., Curto-Barredo L., Bertolín-Colilla M., Ferran M., Serra-Baldrich E., Pujol R.M., Santamaria-Babí L.F.. Allergen sensitization stratifies IL-31 production by memory T cells in atopic dermatitis patients. Frontiers in Immunology. 2023; 14DOI:10.3389/fimmu.2023.1124018. PMID:36993985. IF:5.700(Q1/3D).

01/03/2023 Comparative Effectiveness of Biologics Across Subgroups of Patients with Moderate-to-Severe Plaque Psoriasis: Results at Week 12 from the PSoHO Study in a Real-World Setting

Lynde, C, Riedl, E, Maul, JT, Torres, T, Pinter, A, Fabbrocini, G, Daniele, F, Brnabic, A, Reed, C, Wilhelm, S, Holzkamper, T, Schuster, C, Puig, L. Comparative Effectiveness of Biologics Across Subgroups of Patients with Moderate-to-Severe Plaque Psoriasis: Results at Week 12 from the PSoHO Study in a Real-World Setting. ADVANCES IN THERAPY. 2023; 40(3)DOI:10.1007/s12325-022-02379-9. PMID:36515803. IF:3.400(Q2/3D).

01/03/2023 Generalized Pustular Psoriasis: A Review on Clinical Characteristics, Diagnosis, and Treatment

Rivera-Diaz, R, Dauden, E, Carrascosa, JM, de la Cueva, P, Puig, L. Generalized Pustular Psoriasis: A Review on Clinical Characteristics, Diagnosis, and Treatment. Dermatology and Therapy. 2023; 13(3)DOI:10.1007/s13555-022-00881-0. PMID:36635445. IF:3.500(Q1/3D).

01/03/2023 Clinical and endoscopic outcomes of patients with colonic Crohn's disease treated with 5-aminosalicylates as monotherapy

Castillo-Regalado E., Ríos R., Aràjol C., Gely C., Márquez L., Calafat M., González-Muñoza C., Cañete F., Mesonero F., Guardiola J., Garcia-Planella E., Mañosa M., Domènech E.. Clinical and endoscopic outcomes of patients with colonic Crohn's disease treated with 5-aminosalicylates as monotherapy. Gastroenterologia y Hepatologia. 2023; 46(3)DOI:10.1016/j.gastrohep.2022.09.003. PMID:36179946. IF:2.200(Q3/6D).

08/02/2023 Tyk2 Targeting in Immune-Mediated Inflammatory Diseases

Rusinol, L, Puig, L. Tyk2 Targeting in Immune-Mediated Inflammatory Diseases. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2023; 24(4)DOI:10.3390/ijms24043391. PMID:36834806. IF:4.900(Q1/3D).

01/02/2023 Efficacy and Safety of JAK1 Inhibitor Abrocitinib in Atopic Dermatitis

Iznardo, H, Roe, E, Serra-Baldrich, E, Puig, L. Efficacy and Safety of JAK1 Inhibitor Abrocitinib in Atopic Dermatitis. Pharmaceutics. 2023; 15(2)DOI:10.3390/pharmaceutics15020385. PMID:36839707. IF:4.900(Q1/2D).

01/01/2023 Allergic contact dermatitis to alkyl glucosides: Epidemiological situation in Spain

Tous-Romero, F, Gimenez-Arnau, AM, Sanz-Sanchez, T, Perez, RG, Carrascosa-Carrillo, JM, Zaragoza-Ninet, V, Cordoba-Guijarro, S, Gatica-Ortega, ME, Miquel-Miquel, J, Borrego-Hernando, L, Ruiz-Gonzalez, I, Serra-Baldrich, E, Silvester-Salvador, JF, Mercader-Garcia, P, Sanchez-Perez, J, Rodriguez-Serna, M, Pastor-Nieto, A, Hervella-Garcia, M, Garcia-Doval, I, Ortiz-de Frutos, FJ. Allergic contact dermatitis to alkyl glucosides: Epidemiological situation in Spain. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2023; 37(3)DOI:10.1111/jdv.18595. PMID:36153692. IF:8.500(Q1/1D).

01/01/2023 SARS-CoV-2 infection in patients with melanoma: results of the Spanish Melanoma Group registry

Gonzalez-Cao, M, Puertolas, T, Martinez-Vila, C, Carrera, C, Seral, CM, Rodriguez-Jimenez, P, Sequero, S, Cerezuela-Fuentes, P, Ochoa, RF, Munoz, E, Basa, MA, Martin-Liberal, J, Soria, A, Moreno, JFR, Marquez-Rodas, I, Criado, PL, Manzano, JL, Lopez-Castro, R, De Miguel, PA, Villalobos, L, Algarra, SM, Gonzalez-Barrallo, I, Boada, A, Castano, AG, Puig, S, Crespo, G, Fra, PL, Zamora, CA, Rodriguez, MF, Valles, L, Drozdowskyj, A, Gardeazabal, J, Fernandez-Morales, LA, Rodrigo, A, Cruz, R, Yelamos, O, Rubio, B, Mujica, K, Provencio, M, Berrocal, A. SARS-CoV-2 infection in patients with melanoma: results of the Spanish Melanoma Group registry. Clinical & Translational Oncology. 2023; 25(3)DOI:10.1007/s12094-022-02985-7. PMID:36566266. IF:2.800(Q2/5D).

01/01/2023 Elevating the Standard of Care for Patients with Psoriasis: 'Calls to Action' from Epicensus, a Multistakeholder Pan-European Initiative

Koren J., Lambert, JLW, Thomsen S.F., McAteer H., Fabbrocini G., Corazza V., Jullien D., Augustin M., Warren R.B., de Rie M.A., Lazaridou E., Puig L., Guillevin L., Grosser M., Boehncke, WH. Elevating the Standard of Care for Patients with Psoriasis: 'Calls to Action' from Epicensus, a Multistakeholder Pan-European Initiative. Dermatology and Therapy. 2023; 13(1)DOI:10.1007/s13555-022-00846-3. PMID:36484915. IF:3.500(Q1/3D).

01/01/2023 Sensitization to isothiazolinones in the Spanish Contact Dermatitis Registry (REIDAC): 2019–2021 epidemiological situation

Hernández Fernández C.P., Borrego L., Mercader García P., Giménez Arnau A.M., Sánchez Pérez J., Silvestre Salvador J.F., González Pérez R., Sanz Sánchez T., Sánchez Gilo A., Melé Ninot G., Zaragoza Ninet V., Miquel Miquel F.J., Carrascosa Carrillo J.M., Córdoba Guijarro S., Gatica Ortega M.E., Ruiz González I., Serra Baldrich E., Tous Romero F., Rodríguez Serna M., Pastor Nieto M.A., Pérez Feal P., Hervella Garcés M., de Vega Martínez M., García Doval I.. Sensitization to isothiazolinones in the Spanish Contact Dermatitis Registry (REIDAC): 2019–2021 epidemiological situation. CONTACT DERMATITIS. 2023; 88(3)DOI:10.1111/cod.14251. PMID:36403138. IF:4.800(Q1/2D).

01/01/2023 Development and validation of a minimally invasive and image-guided tape stripping method to sample atopic skin in children

Yélamos O., Andersen D., Pont M., Iglesias P., Potrony M., Domínguez M., Herrero A., Alejo B., Mateu J., Røpke M., Danneskiold-Samsøe N.B., Malvehy J., Guy R.H., Brix S., Puig S.. Development and validation of a minimally invasive and image-guided tape stripping method to sample atopic skin in children. CLINICAL AND EXPERIMENTAL DERMATOLOGY. 2023; 48(2)DOI:10.1093/ced/llac040. PMID:36730521. IF:3.700(Q1/2D).

01/01/2023 Psoriasis treatment does not impair the immunogenicity of ChAOx1-S[recombinant] COVID-19 vaccination

Puig L.. Psoriasis treatment does not impair the immunogenicity of ChAOx1-S[recombinant] COVID-19 vaccination. BRITISH JOURNAL OF DERMATOLOGY. 2023; 188(2)DOI:10.1093/bjd/ljac081. PMID:36763894. IF:11.000(Q1/1D).

01/01/2023 Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes

Egeberg A., Merola J.F., Schäkel K., Puig L., Mahar P.D., Wang I.Y., Pavo I., Schuster C., Griffiths C.E.M.. Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes. Frontiers in Medicine. 2023; 9DOI:10.3389/fmed.2022.1092688. PMID:36777159. IF:3.100(Q1/2D).

01/01/2023 The social value of a PASI 90 or PASI 100 response in patients with moderate-to-severe plaque psoriasis in Spain

Maravilla-Herrera P., Merino M., Alfonso Zamora S., Balea Filgueiras J., Carrascosa Carrillo J.M., Delgado Sánchez O., Dolz Sinisterra F., García-Ruiz A., Herranz Pinto P., Manfredi A., Martínez Olmos J., Morales de los Ríos Luna P., Puig L., Ros S., Hidalgo-Vega Á.. The social value of a PASI 90 or PASI 100 response in patients with moderate-to-severe plaque psoriasis in Spain. Frontiers in Public Health. 2023; 11DOI:10.3389/fpubh.2023.1000776. PMID:36778548. IF:3.000(Q2/3D).

01/01/2023 The impact of achieving and maintaining near-complete or complete skin clearance on patient quality of life in moderate-to-severe psoriasis

Ryan C., Puig L., Zema C., Thompson E.H.Z., Yang M., Wu E., Bensimon A., Huang X., Joshi A.D., Elewski B.. The impact of achieving and maintaining near-complete or complete skin clearance on patient quality of life in moderate-to-severe psoriasis. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2023; 88(1)DOI:10.1016/j.jaad.2021.12.032. PMID:34954285. IF:12.800(Q1/1D).

16/12/2022 Secukinumab is effective and safe in the long-term treatment of plaque psoriasis in a daily practice setting: Multicenter study in 384 Spanish patients

Chicharro, P, Llamas-Velasco, M, Armesto, S, Acosta, EH, Vidal, D, Vilarrasa, E, Rivera-Diaz, R, De-la-Cueva, P, Martorell-Calatayud, A, Ballesca, F, Belinchon, I, Carretero, G, Rodriguez, L, Romero-Mate, A, Pujol-Montcusi, J, Salgado, L, Sahuquillo-Torralba, A, Coto-Segura, P, Rodriguez, OB, Feltes, R, Riera-Monroig, J, Dauden, E. Secukinumab is effective and safe in the long-term treatment of plaque psoriasis in a daily practice setting: Multicenter study in 384 Spanish patients. Dermatologic Therapy. 2022; 35(12)DOI:10.1111/dth.15929. PMID:36223184. IF:3.600(Q1/3D).

02/12/2022 Biologic treatment of psoriasis in oncologic patients

Rusinol, L, Camina-Conforto, G, Puig, L. Biologic treatment of psoriasis in oncologic patients. EXPERT OPINION ON BIOLOGICAL THERAPY. 2022; 22(12)DOI:10.1080/14712598.2022.2152322. PMID:36422998. IF:4.600(Q2/3D).

01/11/2022 Drug survival of adalimumab biosimilars in real-world treatment of psoriasis: A Spanish multicenter study

Lopez-Ferrer, A, Vilarrasa, E, Armesto, S, Santos-Juanes, J, Galache, C, Carretero, G, Sahuquillo, A, Salgado-Boquete, L, del Alcazar, E, Gonzalez-Cantero, A, Martorell, A, Rivera-Diaz, R, Mitxelena-Ezeiza, J, Mateu, A, Belinchon, I, Llamas-Velasco, M, Riera-Monroig, J, Lazaro, A, Lopez-Estebaranz, JL, Gich, I, Puig, L. Drug survival of adalimumab biosimilars in real-world treatment of psoriasis: A Spanish multicenter study. Dermatologic Therapy. 2022; 35(11)DOI:10.1111/dth.15831. PMID:36109488. IF:3.600(Q1/3D).

01/09/2022 Secukinumab is effective in the treatment of recalcitrant palmoplantar psoriasis and palmoplantar pustular psoriasis in a daily practice setting

Reolid, A, Armesto, S, Sahuquillo-Torralba, A, Torres, T, Feltes, R, Vilarrasa, E, Belincho, I, de la Cueva, P, Rodriguez, L, Romero-Mate, A, Vidal, D, Coto-Segura, P, Herrera-Acosta, E, Riera-Monroig, J, Salgado, L, Llamas-Velasco, M, Dauden, E. Secukinumab is effective in the treatment of recalcitrant palmoplantar psoriasis and palmoplantar pustular psoriasis in a daily practice setting. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2022; 87(3)DOI:10.1016/j.jaad.2022.05.047. PMID:35640798. IF:13.800(Q1/1D).

01/09/2022 SARS-CoV-2 seroprevalence in blood donors before and after the first wave in Catalonia (Spain)

Piron, M, Jane, M, Ciruela, P, Basile, L, Martinez, A, Puig, L, Bes, M, Sauleda, S. SARS-CoV-2 seroprevalence in blood donors before and after the first wave in Catalonia (Spain). Blood Transfusion. 2022; 20(5)DOI:10.2450/2022.0232-21. PMID:35175189. IF:3.700(Q2/4D).